

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.002 mL	10.010 mL	20.020 mL
5 mM	0.4004 mL	2.002 mL	4.004 mL
10 mM	0.2002 mL	1.001 mL	2.002 mL
50 mM	0.040 mL	0.2002 mL	0.4004 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Grove RA, et al. Leukocyte counts in cerebrospinal fluid and blood following finategrast treatment in subjects with relapsing forms of multiple sclerosis. *Eur J Neurol*. 2013 Jul;20(7):1032-42.
- Evbomwan M O, et al. Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist. *Blood*. 2017; 130: 3197.
- Herman SE, et al. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. *Clin Cancer Res*. 2015;21(20):4642-4651.
- Szenes E, et al. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. *Leukemia*. 2020;34(9):2498-2502.
- Rahimi H, et al. Aberrant regulation of the integrin very late antigen-4 in systemic lupus erythematosus. *Lupus*. 2013;22(3):297-306.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481